|
||
Enstilar Pregnancy |
||
Animal studies have not been reported with Betamethasone (Enstilar)-Calcipotriene (Enstilar) topical. Animal studies have revealed evidence of teratogenicity with corticosteroids administered systemically at relatively low doses. Betamethasone (Enstilar) has been shown to be teratogenic when administered subcutaneously in mice and rabbits. Calcipotriene (Enstilar) has been shown to be fetotoxic in animals when given systemically. There are no controlled data in human pregnancy. FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.
FDA pregnancy category: C Potential benefit should outweigh the potential risk.
Caution is recommended. Excreted into human milk: Unknown Excreted into animal milk: Unknown The effects in the nursing infant are unknown.
It is unknown if there is sufficient systemic absorption with topically administered Betamethasone (Enstilar) or Calcipotriene (Enstilar) to have detectable quantities in human milk. Betamethasone (Enstilar)-Calcipotriene (Enstilar) topical suspension should not be used on the breast when nursing.
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|